The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Support for biologics manufacturability and Industry 4.0 initiatives
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Subscribe To Our Newsletter & Stay Updated